INBRAIN Neuroelectronics
Financials
Estimates*
EUR | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Revenues | <1m | <1m | <1m | <1m | <1m |
% growth | - | 79 % | 234 % | 60 % | 8 % |
EBITDA | - | (<1m) | (<1m) | - | - |
% EBITDA margin | - | (32 %) | (195 %) | - | - |
Profit | - | (<1m) | (<1m) | - | - |
% profit margin | - | (74 %) | (222 %) | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
€1.0m | Seed | ||
€14.4m | Series A | ||
€1.1m | Grant | ||
* | €2.5m | Grant | |
* | N/A | - | |
* | €3.0m | Convertible | |
* | €20.0m | Debt | |
Total Funding | €22.0m |
Recent News about INBRAIN Neuroelectronics
EditOperator of a medical device company intended to provide high-density and resolution graphene intelligent neural systems. The company uses graphene to develop neural interfaces that can read and modulate brain activity at high resolution and detect therapy-specific biomarkers and trigger highly focal adaptive neuromodulation, helping patients to obtain optimal results in personalized neurological therapies.
Keywords: Pharmaceuticals and Biotechnology, Artificial Intelligence Technology, Bioelectronics Devices, Brain Computer Interface, Neural System, Neuro Sciences, Neuroelectronic Cell, Neurological Therapeutics, Neurological Therapy, Neurological Therapy Provider, Neurotechnology, Peripheral Nerve Modulation.